Holen Sie sich die Stockscreener-App
14.10
0.49%
-0.07
Handel nachbörslich:
14.10
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt RDY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$14.17
Offen:
$14.1
24-Stunden-Volumen:
1.59M
Relative Volume:
2.09
Marktkapitalisierung:
$2.35B
Einnahmen:
$3.47B
Nettoeinkommen (Verlust:
$668.83M
KGV:
3.7967
EPS:
3.7138
Netto-Cashflow:
$253.46M
1W Leistung:
-6.00%
1M Leistung:
-11.51%
6M Leistung:
+3.28%
1J Leistung:
+5.41%
1-Tages-Spanne:
$13.97
$14.18
1-Wochen-Bereich:
$13.97
$14.95
52-Wochen-Spanne:
$12.90
$16.89
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
Vergleichen Sie RDY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| RDY | 14.10 | 2.35B | 3.47B | 668.83M | 253.46M | 3.7138 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-01-11 | Herabstufung | Jefferies | Buy → Underperform |
| 2023-08-29 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-05-18 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-03-17 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-01-30 | Eingeleitet | JP Morgan | Underweight |
| 2022-11-14 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-01-03 | Fortgesetzt | BofA Securities | Neutral |
| 2021-07-27 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-02-02 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-09-18 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-09-18 | Hochstufung | Investec | Sell → Hold |
| 2020-01-28 | Herabstufung | CLSA | Buy → Outperform |
| 2020-01-27 | Herabstufung | CLSA | Buy → Outperform |
| 2020-01-09 | Hochstufung | Citigroup | Sell → Buy |
| 2019-11-04 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-09-04 | Hochstufung | Credit Suisse | Underperform → Outperform |
| 2019-07-01 | Hochstufung | Macquarie | Neutral → Outperform |
| 2019-06-20 | Eingeleitet | Deutsche Bank | Hold |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-20 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-02-19 | Hochstufung | CLSA | Outperform → Buy |
| 2019-01-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2017-09-21 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-08-31 | Hochstufung | CLSA | Underperform → Outperform |
| 2017-07-28 | Herabstufung | CLSA | Underperform → Sell |
| 2016-07-27 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2016-07-27 | Herabstufung | Jefferies | Hold → Underperform |
| 2016-02-10 | Hochstufung | Credit Agricole | Underperform → Buy |
| 2015-11-10 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Dr Reddys Laboratories Ltd Adr Aktie (RDY) Neueste Nachrichten
Jharkhand Elections Phase 2: Richest candidate declares assets worth Rs 402 cr – Check list of top 10 wealthiest candidates - The Financial Express
Jharkhand Phase 2 Elections 2024: 122 candidates with serious criminal cases get tickets, shows ADR report - The Financial Express
ADR, GDR Listings of Indian companies - Goodreturns
Earnings call: Dr. Reddy's reports robust growth and strategic expansions By Investing.com - Investing.com Australia
Earnings call: Dr. Reddy's reports robust growth and strategic expansions - Investing.com India
Zollinger-Ellison Syndrome (Gastrinoma) Global Clinical Trials Review 2024: Country (G7 & E7), Phase, Trial Status, End Points Status and Sponsor Type - GlobeNewswire Inc.
Dr. Reddy's stock poised for recovery with new US launches and global OTC gains—BofA - Investing.com India
Dr. Reddy's stock poised for recovery with new US launches and global OTC gains—BofA By Investing.com - Investing.com South Africa
Dr. Reddy’s Labs ADR earnings missed by $0.85, revenue topped estimates - Investing.com Australia
Asian Equities Traded in the US as American Depositary Receipts Climb Higher Friday - MSN
Dr. Reddy’s shares trade ex-split today. Stock up 2% - The Economic Times
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading - MSN
Indian stock market: 8 things that changed for market overnight- Gift Nifty, US retail sales, ECB rate cut to Q2 results | Stock Market News - Mint
Infosys, Wipro ADRs down 3% on NYSE after Q2 results even as S&P, Dow drift near record-highs | Stock Market News - Mint
Zacks Research Issues Positive Forecast for RDY Earnings - MarketBeat
Top gainers and losers for today on October 16: HDFC Life, Dr Reddy’s Labs, Grasim lead NIFTY movers - Upstox
Denmark Basal Cell Carcinoma Treatment Market Size & Outlook, 2030 - Grand View Research
Saudi Arabia Basal Cell Carcinoma Treatment Market Size & Outlook, 2030 - Grand View Research
Haryana Election 2024: 95 candidates have serious criminal cases against them, 11 with cases of crime against women, says report - The Financial Express
Side-effects of banned drug Nimesulide still reported in children: Report | Today News - Mint
Dr. Reddy’s Announces Share Subdivision Date - TipRanks
Dr. Reddy’s Subsidiary Chirotech Dissolved - TipRanks
Haryana Elections 2024: Capt. Abhimanyu, Savitri Jindal among wealthiest candidates for October 5 polls | Mint - Mint
Assam: Mobile internet services to be disabled for eight hours on Sunday, here's why | Today News - Mint
Announcements Updates: Compliances-Reg. 39 (3)Details of Loss of Certificate / Duplicate Certificate - The Economic Times
Apni Party's Altaf Bukhari, BJP's Devender Rana among 3 richest candidates in Jammu and Kashmir assembly poll fray | Mint - Mint
Dr. Reddy's Labs ADR Sees RS Rating Rise To 72 - Investor's Business Daily
Dr. Reddy’s Empowers Employees with Stock Options - TipRanks
Deutsche Bank Appointed as Depositary Bank for the Sponsored American Depositary Receipt Program of Radiopharm Theranostics Limited - Business Wire
Mondrian Investment Partners LTD Has $11.56 Million Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY) - MarketBeat
Dr. Reddy's Laboratories Share Price Today Live Updates: Dr. Reddy's Laboratories Sees 1.48% Decline, Cu... - The Economic Times
Dr. Reddy's Laboratories Share Price Live Updates: Dr. Reddy's Laboratories Sees Minor Price Dip Amidst ... - The Economic Times
Dr. Reddy’s Shareholders Approve Stock Split - TipRanks
US FDA closes inspection of Dr Reddy’s API unit - BusinessLine
Singapore Anticoagulant Reversal Drugs Market Size & Outlook, 2027 - Grand View Research
Mexico Antiviral Drugs Market Size & Outlook, 2022-2030 - Grand View Research
The United States Antiviral Drugs Market Size & Outlook, 2030 - Grand View Research
Latin America Antiviral Drugs Market Size & Outlook, 2030 - Grand View Research
Weekly Upgrades and Downgrades - InvestorPlace
Dr. Reddy's Stock Hit All-Time High Last Month. Ready To Climb Again? - Investor's Business Daily
The United States Erythropoietin Drugs Market Size & Outlook, 2030 - Grand View Research
Volume Updates: Dr. Reddy's Laboratories Sees Significant Surge in Trading Volume - The Economic Times
Dr. Reddy’s Approves Employee Share Allotment - TipRanks
Stocks in news: Interarch, Dr Reddy's Labs, Ceigall, ONGC, Akums, Trent, Zydus Life & Uno Minda - Business Today
Finanzdaten der Dr Reddys Laboratories Ltd Adr-Aktie (RDY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.79%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):